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Abstract
Thrombocytopenia is common in patients with myelofibrosis (MF) and is a well-established adverse prognostic factor.
Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not
been evaluated in patients with severe thrombocytopenia (platelet counts <50×109/L). Pacritinib, a novel
JAK2/interleukin-1 receptor-associated kinase 1 inhibitor, has been studied in two phase III trials (PERSIST-1 and PERSIST2), both of which enrolled patients with MF and severe thrombocytopenia. In order to better characterize treatment
outcomes for this population with advanced disease, we present a retrospective analysis of efficacy and safety data in
the 189 patients with severe thrombocytopenia treated in the PERSIST studies. The proportion of patients in the pacritinib
group meeting efficacy endpoints was greater than in the BAT group for ≥35% spleen volume reduction (23% vs. 2%,
P=0.0007), ≥50% modified Total Symptom Score reduction (25% vs. 8%, P=0.044), and self-reported symptom benefit
(“much” or “very much” improved; 25% vs. 8%, P=0.016) at the primary analysis time point (week 24). The adverse event
profile of pacritinib was manageable, and dose modification was rarely required. There was no excess in bleeding or death
in pacritinib-treated patients. These results indicate that pacritinib is a promising treatment for patients with MF who
lack safe and effective therapeutic options due to severe thrombocytopenia.

Introduction
Patients with myelofibrosis (MF) who have severe thrombocytopenia (platelet counts <50×109/L) comprise a subset
of patients with cytopenic MF who generally have more advanced disease, including anemia, greater risk of bleeding,
worse symptom burden, higher risk of leukemic transformation, and shorter survival (median 15 months) compared with patients with higher platelet counts.1-3 These
patients lack effective treatment options and are often excluded from clinical trials. Neither ruxolitinib nor fedratinib,
the only drugs currently approved for MF, has been studied
in patients presenting with severe thrombocytopenia, and
neither drug has a product label with a recommended
starting dose for this population.4-9 Furthermore, both have
been shown to cause treatment-related thrombocytopenia,
which requires dose modification and may result in reduced efficacy. For example, patients treated with ruxolitinib at ≤10 mg twice a day (BID) were less likely to achieve

significant spleen volume responses.10 Development of
cytopenias was the most common reason for patients discontinuing ruxolitinib.11 Ruxolitinib has been tested in patients with moderate thrombocytopenia (platelet counts
50-100×109/L). In the phase Ib EXPAND study, dose interruptions or reductions were required in 89% of patients
who had platelet counts 50-74×109/L, and 78% experienced
grade 3 or 4 thrombocytopenia as an adverse event.12 In the
phase IIIb expanded-access JUMP study, 55% of patients
who started on ruxolitinib 5 mg BID required further dose
reduction, and grade 3 or 4 thrombocytopenia was a common adverse event.13 There is a significant unmet need for
effective and safe therapies for patients living with MF and
experiencing severe thrombocytopenia, who may comprise
up to 35% of the MF population.14
Pacritinib is a novel inhibitor of Janus kinase 2 (JAK2) and
interleukin-1 receptor-associated kinase 115 currently in development for patients with MF and thrombocytopenia.
Two randomized controlled phase III trials, PERSIST-116 and
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PERSIST-2,17 have compared the efficacy and safety of pacritinib versus best available therapy (BAT). Because earlier
phase I-II studies had shown that pacritinib has limited
myelosuppressive properties,18 neither phase III study had
a lower limit on platelet counts, and both included patients
with moderate and severe thrombocytopenia. The PERSIST
studies represent the largest published data set of patients
with MF and severe thrombocytopenia treated in randomized controlled trials. In order to better characterize treatment outcomes for this population with advanced disease,
we present pooled data from patients with severe thrombocytopenia treated in PERSIST-1 and PERSIST-2 and describe the efficacy and safety profiles of pacritinib
compared to BAT.

Methods
The PERSIST-1 (clinicaltrials gov. Identifier: NCT01773187)
and PERSIST-2 (clinicaltrials gov. Identifier: NCT02055781)
study designs and methodology have been previously described.16,17 Key features of both studies are summarized
below. The study protocols were approved by the Institutional Review Boards at each study site and the study was
conducted in accordance with the Declaration of Helsinki.
All patients provided written informed consent. Both
studies included adult patients with either primary or secondary MF. Patients had intermediate-1, intermediate-2, or
high-risk disease, as categorized by the Dynamic International Prognostic Scoring System, and palpable splenomegaly ≥5 cm below the left costal margin. PERSIST-1
enrolled patients regardless of platelet count, while PERSIST-2 was restricted to patients with platelet counts
≤100×109/L. Both studies included patients with severe
thrombocytopenia (platelet counts <50x109/L) at baseline;
this population comprised 16% of patients in PERSIST-1 and
45% in PERSIST-2. Prior use of JAK inhibitors was permitted
only in PERSIST-2. PERSIST-1 randomized patients 2:1 to receive pacritinib 400 mg daily or BAT. PERSIST-2 randomized
patients 1:1:1 to receive pacritinib 400 mg daily, pacritinib
200 mg BID, or BAT. Randomization was stratified by baseline platelet count. BAT included any available physicianselected treatment, including “watch and wait” (i.e., no
active treatment). Ruxolitinib was included as an option
only in PERSIST-2. Fedratinib was not available as BAT in
either study. Patients randomized to receive BAT were
allowed to cross over to pacritinib at 24 weeks or at disease progression. Safety and efficacy data were censored
at the time of crossover.
Statistical analysis
Patients in PERSIST-1 and PERSIST-2 with baseline platelet counts <50×109/L were included in the analysis. Efficacy endpoints were assessed at week 24 and included

S. Verstovsek et al.
the percentage of patients achieving ≥35% spleen volume
response (SVR), the percentage achieving ≥50% reduction
in the modified Total Symptom Score (TSS) v2.0,19 and the
percentage reporting symptoms as “much” or “very much”
improved on the Patient Global Impression of Change
scale. Cardiac and hemorrhagic events were defined using
Standardized MedDRA Queries. Since the PERSIST-2 study
was terminated prematurely due to a clinical hold, intention-to-treat (ITT) efficacy analyses included all randomized patients in PERSIST-1 and the 71% in PERSIST-2 who
were randomized at least 22 weeks prior to the hold. As
the TSS instrument administered during PERSIST-1 was
changed from v1.0 to v2.0 part-way through the study, only
patients who had completed v2.0 at baseline were included in the ITT TSS analysis. Safety analyses included
all treated patients (Online Supplementary Figure S1). Differences in baseline characteristics between groups were
evaluated using the chi-square test (categorical variable)
or the Wilcoxon rank-sum test (continuous variables). The
Breslow and Day homogeneity test was performed to
measure the magnitude of treatment effect on the response in the presence of a prior JAK or MF diagnosis. For
efficacy outcomes, Fisher’s exact test was used to perform between-group categorical analysis; the Wilcoxon
exact test was used for continuous outcome variables.

Results
Patient characteristics
In total, 192 patients (133 pacritinib, 59 BAT) with severe
thrombocytopenia were enrolled in PERSIST-1 and PERSIST-2. Of these, 189 (132 pacritinib, 57 BAT) received at
least one dose of study drug. There were 152 patients (104
pacritinib, 48 BAT) included in the ITT efficacy population,
and 117 patients (80 pacritinib, 37 BAT) completed the TSS
v2.0 at baseline (Online Supplementary Figure S1). As
shown in Table 1, median age was 69 years (range, 50–91).
The majority of patients (72%) had primary MF, with a
median time from diagnosis of 2.0 years. Approximately
one-third of patients (34%) had received prior treatment
with a JAK2 inhibitor. Median platelet count at baseline
was 28×109/L, 63.5% had hemoglobin <10 g/dL, and 48%
had ≥1% peripheral blood blasts. Approximately half of the
patients (49%) had grade 3 marrow fibrosis, and 38% had
low or normal marrow cellularity (≤40%). The most common therapies selected as BAT were “watch and wait”
(37%; with 25% receiving only “watch and wait” for the
duration of the study), ruxolitinib (30%; only available for
PERSIST-2), hydroxyurea (28%), and prednisone (12%). The
duration of study drug exposure was similar for pacritinib
and BAT (median 5.5 and 5.2 months, respectively), although 33% of patients on BAT cycled through multiple
therapies on study. Shorter treatment durations were due,
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in part, to truncation at the time of the clinical hold, as mained 400 mg at both weeks 12 and 24, whereas patients
46% of patients were still on pacritinib at the time of the in PERSIST-2 who received ruxolitinib as BAT were preclinical hold. The median total daily dose of pacritinib re- scribed a median post-titration dose of 10 mg and were

Table 1. Baseline patient and disease characteristics in patients treated with pacritinib or best available therapy

Age, median (range)

Pacritinib (N = 132)

BAT (N = 57)

P-value**

69 (50-91)

69 (50-84)

0.95

80 (61)

28 (49)

0.14

100/132 (76)
32/132 (24)

42/55 (76)
13/55 (24)

43 (33)

21 (37)

Male sex, N (%)
ECOG PS, N* (%)
0-1
2-3

0.93

Prior JAK2 inhibitor, N (%)
MF diagnosis, N (%)
Primary MF
PPV-MF
PET-MF

0.17
98 (74)
20 (15)
14 (11)

38 (67)
8 (14)
22 (39)

2.0 (0–27)

2.6 (0–14)

26 (20)
63 (48)
43 (33)

5 (9)
30 (53)
22 (39)

Reticulin and collagen fibrosis staging, N* (%)
MF 0-1
MF 2
MF 3

18/122 (15)
38/122 (31)
66/122 (54)

11/52 (21)
15/52 (29)
26/52 (50)

Bone marrow cellularity, N* (%)
<20%
20-40%
41-100%

27/110 (25)
18/110 (16)
65/110 (59)

18/49 (37)
8/49 (16)
23/49 (47)

Bone marrow blast category, N* (%)
≥1%
<1%

96/115 (84)
19/115 (17)

41/50 (82)
11/50 (18)

Time since MF diagnosis (years), median (IQR)
DIPSS risk category, N (%)
Intermediate-1
Intermediate-2
High

Peripheral blood blasts category, N* (%)
≥1%
<1%

0.57

0.72
0.17

0.58

0.26

0.82

0.18
60/118 (51)
58/118 (49)

31/50 (62)
19/50 (38)

29 (6-49)

25 (5-49)

0.27

85/132 (64)

35/56 (63)

0.80

38 (29)
61 (46)
33 (25)

20 (35)
23 (40)
14 (25)

Spleen volume at baseline (cm3)‡, median (IQR)

2,566 (1,633-3,680)

2,466 (1,786-3,727)

0.87

Modified TSS score at baseline‡, median (IQR)

17 (12-29)

7 (12-27)

0.94

35 (27)
97 (73)

15 (26)
42 (74)

Platelet count (109/L), median (range)
Hemoglobin <10 g/dL, N* (%)
RBC transfusion dependence†, N (%)
Dependent
Independent
Indeterminate

0.66

Study enrollment, N (%)
PERSIST-1
PERSIST-2

0.98

BAT: best available therapy; DIPSS: Dynamic International Prognostic Scoring System; ECOG PS: Eastern Cooperative Oncology Group performance status; IQR: interquartile range; JAK2: Janus kinase 2; MF: myelofibrosis; PET: post-essential thrombocythemia; PPV: post-polycythemia vera; RBC: red blood cell; TSS: Total Symptom Score. *Denominators represent non-missing values. **Chi-square test for categorical
variables and Wilcoxon rank-sum test for continuous variables. †Per Gale criteria.24 ‡Baseline values reported for efficacy population.
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on this treatment for a median duration of only 3.45 with higher response rates regardless of whether patients
months.
had received prior treatment with JAK2 inhibitors or
whether they had primary versus secondary MF (Table 2).
Efficacy
The percentage of patients treated with pacritinib who Safety
achieved a 24-week ≥35% SVR response was greater than The treatment-emergent adverse events (TEAE) that dethe percentage of patients treated with BAT (23.1% vs. 2.1%, veloped in patients with severe thrombocytopenia were
P=0.0007) (Figures 1 and 2A). Higher response rates were consistent with the overall PERSIST study results and were
observed in patients treated with pacritinib 200 mg BID generally grade 1 or 2 in severity (Table 3). The most comcompared with those on 400 mg daily (29.0% vs. 20.5%). mon non-hematologic TEAE in pacritinib-treated patients
The median percentage change in spleen volume was were diarrhea (60.6%; 5.3% grade 3-4), nausea (30.3%; 1.5%
greater for pacritinib-treated patients than for BAT-treated grade 3-4), and vomiting (26.5%; 0.8% grade 3-4). These
patients (-29.4% vs. -1.3%, P<0.0001), and the percentage gastrointestinal events were observed more frequently in
of patients who experienced any improvement (>0%) in the pacritinib group but rarely led to dose reduction (3.0%
SVR was higher in the pacritinib compared with the BAT for diarrhea, 1.5% for nausea) or discontinuation (3.8% for
group (56.7% vs. 33.3%, P=0.0089). Similarly, pacritinib- diarrhea, 0% for nausea). The most common hematologic
treated patients were more likely to achieve ≥50% mod- TEAE in this thrombocytopenic population among pacritiified TSS reduction at week 24 compared to BAT-treated nib-treated patients were thrombocytopenia (34.8%) and
patients (25% vs. 8.1%, P=0.0441) (Figures 1 and 2B), and anemia (31.8%). Hematologic TEAE were generally grade 3
the median reduction in modified TSS score was greater or 4 given the degree of cytopenias present at baseline,
with pacritinib than with BAT (-30.3% vs 0%, P=0.0036). but these rarely led to dose reduction (4.5% and 2.3% for
Response rates for TSS were similar between the two pa- thrombocytopenia and anemia, respectively) or discontinucritinib doses. The percentage of patients who experi- ation (3.8% and 3.8%, respectively). Among patients reenced any improvement (>0%) in TSS was higher in the maining on study, hemoglobin and platelet counts were
pacritinib compared to the BAT group (53% vs. 32%, stable through week 24 (Figure 4). While thrombocytopenia
P=0.049). Pacritinib-treated patients were significantly was observed more often on pacritinib, there was no exmore likely than patients treated with BAT to report that cess of hemorrhagic events (pacritinib vs. BAT: grade ≥1,
their symptoms were “very much” or “much” improved at 51.5% vs. 59.6%; grade 3-4, 13.6% vs. 10.5%; fatal, 2% vs.
week 24 (25.0% vs. 8.3%, respectively; P=0.016) (Figure 3). 0%). High-grade and fatal cardiac events were observed at
Subgroup analyses showed that pacritinib was associated similar rates on pacritinib and BAT (grade 3-4, 9.1% vs. 14%;

Figure 1. Efficacy of pacritinib versus best available therapy based on 24-week response rates in patients with severe
thrombocytopenia. Graph depicts the percentage of patients achieving ≥35% spleen volume reduction (SVR), achieving ≥50%
reduction in modified Total Symptom Score (TSS), and reporting symptoms as being “much” or “very much” improved based on
Patient Global Impression of Change (PGIC) at week 24. Percentages are based on all patients randomized at least 22 weeks prior
to the termination of the PERSIST studies (intention-to-treat [ITT] population). BAT: best available therapy; CI: confidence
interval; PAC: pacritinib.
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A

B

Figure 2. Waterfall plots of percentage change from baseline. (A) Change in spleen volume and (B) change in modified Total
Symptom Score (TSS) at week 24 in patients with severe thrombocytopenia. Data are shown for evaluable patients treated with
pacritinib (pooled dose groups) or best available therapy (BAT) (including ruxolitinib, indicated with red asterisks). Gray horizontal
lines indicate responder threshold (35% for spleen volume reduction [SVR], 50% for TSS).

Table 2. Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib
versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype
(primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia)

Response rate at week 24

Pacritinib

BAT

P-value*

Patients with ≥35% spleen volume reduction, % (n/N)
Prior JAK2 inhibitor exposure
Yes
No
MF diagnosis
Primary
Secondary

0.07
17.9 (5/28)
17.9 (5/28)

7.7 (1/13)
0 (0/35)
0.52

24.0 (18/75)
20.7 (6/29)

3.1 (1/32)
0 (0/16)

Patients with ≥50% reduction in modified TSS, % (n/N)
Prior JAK2 inhibitors
Yes
No
MF diagnosis
Primary
Secondary

17.9 (5/28)
28.8 (15/52)
30.4 (17/56)
12.0 (3/25)

15.4 (2/13)
4.2 (1/24)
12.5 (3/24)
0 (0/12)

0.14

0.43

Patients with “much” or “very much” improved PGIC scores, % (n/N)
Prior JAK2 inhibitors
Yes
No
MF diagnosis
Primary
Secondary

14.3 (4/28)
28.9 (22/76)

15.4 (2/13)
5.7 (2/35)

0.08

0.45
30.7 (23/75)
10.3 (3/29)

12.5 (4/32)
0 (0/16)

BAT: best available therapy; JAK2: Janus kinase 2; MF: myelofibrosis; PGIC: Patient Global Impression of Change; SVR: spleen volume
reduction; TSS: Total Symptom Score. *Breslow and Day homogeneity test
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fatal, 3% vs. 1.8%). Survival was similar between pacritinib- safe and effective therapies. Efficacy was observed irreand BAT-treated patients: hazard ratio (HR): 1.01 (95% con- spective of prior JAK2 inhibitor exposure or MF subtype
fidence interval [CI]: 0.57-1.80).
(primary or secondary), although SVR and symptom response rates were numerically higher in patients who did
not have prior JAK inhibitor exposure. Efficacy in this subgroup of patients with severe thrombocytopenia was simiDiscussion
lar to that observed in the PERSIST studies overall,
In this retrospective analysis, the pacritinib group was as- including in patients with higher platelet counts. The pasociated with improved SVR and symptom response com- tient population described in this analysis had advanced
pared to BAT in patients with MF and severe disease: in addition to severe thrombocytopenia (median
thrombocytopenia, a population with an unmet need for platelet count 28x109/L), about half of the patients had

Figure 3. Self-reported symptoms in patients who completed the Patient Global Impression of Change at week 24 by treatment
group. The percentage of evaluable patients with any improvement in disease symptoms was higher for patients randomized to
pacritinib (84% [47/56]) than for those randomized to best available therapy (BAT) (48% [10/21]).

Figure 4. Median hemoglobin and platelet count over time through week 24. Among patients remaining on study, the median
hemoglobin (A) and platelet count (B) remained stable over time in both pacritinib- and best available therapy (BAT)-treated
patients. IQR: interquartile range.
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Table 3. Most common treatment-emergent adverse events (≥10% all grade or ≥3% grade 3 or 4 in either group) in all treated
patients.*

TEAE, N (%)

Pacritinib (N = 132)

BAT (N = 57)

All grade

Grade 3-4

All grade

Grade 3-4

Diarrhea

80 (60.6)

7 (5.3)

9 (15.8)

9 (15.8)

Thrombocytopenia

46 (34.8)

46 (34.8)

12 (21.1)

12 (21.1)

Anemia

42 (31.8)

42 (31.8)

12 (21.1)

11 (19.3)

Nausea

40 (30.3)

2 (1.5)

7 (12.3

1 (1.8)

Vomiting

35 (26.5)

1 (0.8)

4 (7.0)

1 (1.8)

Epistaxis

21 (15.9)

9 (6.8)

15 (26.3)

1 (1.8)

Peripheral edema

21 (15.9)

2 (1.5)

13 (22.8)

0

Fatigue

19 (14.4)

6 (4.5)

6 (10.5)

3 (5.3)

Dizziness

18 (13.6)

2 (1.5)

2 (3.5)

0

Pyrexia

17 (12.9)

0

6 (10.5)

0

Constipation

17 (12.9)

1 (0.8)

4 (7.0)

0

Abdominal pain

16 (12.1)

2 (1.5)

10 (17.5)

1 (1.8)

Dyspnea

14 (10.6)

2 (1.5)

5 (8.8)

2 (3.5)

Pneumonia

14 (10.6)

10 (7.6)

2 (3.5)

2 (3.5)

Decreased appetite

14 (10.6)

3 (2.3)

4 (7.0)

0

Upper respiratory tract infection

12 (9.1)

0

6 (10.5)

1 (1.8)

Contusion

13 (9.8)

0

6 (10.5)

0

Cough

10 (7.6)

1 (0.8)

7 (12.3)

0

Neutropenia

8 (6.1)

7 (5.3)

4 (7.0)

4 (7.0)

Leukopenia

7 (5.3)

5 (3.8)

2 (3.5)

2 (3.5)

Cardiac failure

5 (3.8)

5 (3.8)

3 (5.3)

2 (3.5)

Atrial fibrillation

2 (1.5)

1 (0.8)

4 (7.0)

2 (3.5)

General health deterioration

4 (3.0)

4 (3.0)

0

0

Lower respiratory tract infection

4 (3.0)

0

2 (3.5)

2 (3.5)

Sepsis

4 (3.0)

2 (1.5)

3 (5.3)

2 (3.5)

Abdominal pain, upper

7 (5.3)

1 (0.8)

3(5.3)

2 (3.5)

BAT: best available therapy; TEAE: treatment-emergent adverse event. *Events were counted regardless of whether they were considered related to study drug. Disease progression as an adverse event is not listed.

circulating blasts ≥1%, and two-thirds had significant anemia (hemoglobin <10 g/dL). These findings are consistent
with previous reports describing the co-occurrence of
these poor prognostic factors in patients with severe
thrombocytopenia.2,3 Furthermore, the patients presented
here had significant burden of disease, with spleen volumes consistent with those reported in patients with
higher platelet counts.6,8,20 Interestingly, the majority of patients had hypo- or normocellular bone marrow, as opposed to the hypercellular marrow typically associated
with myeloproliferative disease.

Pacritinib was tolerated at full doses in patients with severe thrombocytopenia, and the safety profile was consistent with that observed in the PERSIST studies overall,
although rates of bleeding were higher in patients with
severe thrombocytopenia regardless of whether they
were treated with pacritinib or BAT. The most common
adverse events were gastrointestinal, and these were
predominantly low grade and manageable with anti-diarrheals. Despite severe thrombocytopenia at baseline,
discontinuation due to myelosuppression was rare for
patients on pacritinib. Furthermore, hemorrhagic events
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were observed at similar frequencies for pacritinib and
BAT, suggesting that bleeding is more likely associated
with disease-related thrombocytopenia21 and platelet
dysfunction.22
In summary, pacritinib was shown to be more effective
than BAT in reducing splenomegaly and symptom burden
in patients with MF and severe thrombocytopenia. While
this analysis is post hoc and retrospective, the results
highlight the important role that pacritinib may play in the
future therapeutic landscape for patients living with cytopenic MF. In the recent PAC203 phase II dose-finding study
conducted in patients with advanced and heavily pretreated MF, including those with severe thrombocytopenia,
the SVR response rate for patients with severe thrombocytopenia was 17%,23 similar to that observed in this review
(23%); differences could be attributed to the enrollment
of patients with prolonged duration of prior ruxolitinib exposure on PAC203 (median duration of exposure was 2.1
years). The randomized phase III PACIFICA study is currently under way in patients with MF and severe thrombocytopenia comparing pacritinib 200 mg BID with
physicians’ choice of therapy. Results from PACIFICA
should confirm whether pacritinib will be a new therapeutic option for patients with cytopenic MF.
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